FDA approves Bristol's Opdivo for kidney cancer
November 23, 2015 at 15:25 PM EST
Nov 23 (Reuters) - U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's drug, Opdivo, for treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer.
